Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs

Arthritis Rheum. 2007 Mar 15;57(2):343-6. doi: 10.1002/art.22544.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antibodies, Monoclonal / adverse effects*
  • Antirheumatic Agents / adverse effects*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / epidemiology*
  • Crohn Disease / drug therapy
  • Databases, Factual
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / adverse effects
  • Incidence
  • Infliximab
  • Insurance, Health / statistics & numerical data
  • Male
  • Middle Aged
  • Opportunistic Infections / epidemiology*
  • Opportunistic Infections / etiology
  • Predictive Value of Tests
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept